BioCentury | May 5, 2018
Product Development

Rebuilding Biogen’s brain

...form of ischemic stroke that leads to cerebral edema. In March, Biogen acquired neuropsychiatry candidate BIIB104...
BioCentury | Apr 24, 2018
Company News

Biogen looks to ex-U.S. markets for growth

...assets and also return capital to shareholders." In March, Biogen acquired its first neuropsychiatry program: BIIB104...
BioCentury | Jul 5, 2010

3Q Financial Markets Preview: Summer scrapes bottom

Biotech indices may be mostly back to or even below where they started the year, but investors aren't in a hurry to do bottom fishing over the summer. Instead, they are hopeful biotech's bad breaks...
BioCentury | Oct 26, 2009

EPS Watch

EPS Watch Company 3Q09 EPS est 3Q09 EPS actual Outcome Growth from 3Q08 10/23 cls Wk chg % chg Mcap chg 10/23 Mcap Actelion Ltd. (SIX:ATLN) NA CHF 0.88 NA 0% CHF 58.50 -CHF 5.00...
BioCentury | Nov 14, 2005

Around the corner

Around the corner Around the corner No less than seven products have PDUFA dates in 1Q06. Mcap in $M Company Product Indication PDUFA date 11/11 Mcap Celgene (CELG) Revlimid Myelodysplastic syndrome (MDS) 1/7 $9,844.6 Biogen...
Items per page:
1 - 5 of 5